financial guidance
Novartis Sees Steady Q3 Pluvicto Sales Growth as it Readies to Triple Eligible Population in 2025
Premium
The Swiss drugmaker is gearing up to meet a surge in patient demand for the radiopharmaceutical if the FDA approves it in an earlier-line prostate cancer setting.
Myriad Genetics Enters Collaborations to Study MRD, Announces Preliminary Q3 Revenue Estimates
The company is studying the use of its Precise MRD test in the breast cancer setting. It also said it estimates between $210 million and $212 million in Q3 revenue.
Pfizer Oncology Product Revenues Jump 26 Percent in Q2
The firm reported $845 million in Q2 revenue from oncology products gained in its acquisition of Seagen last year.
Keytruda Sales Climb 16 Percent in Q2 as Merck Pursues New Oncology Candidates
The drugmaker updated investors on its three-pronged strategy to diversify its pipeline and not overly rely on its top-selling blockbuster checkpoint inhibitor.
Growth of the prostate cancer radiopharmaceutical was exponential following approval, but has now settled, leading Novartis to ramp up promotional efforts.